Q4 2026 Sanofi India Ltd Earnings Call Transcript
Key Points
- Sanofi India Ltd (BOM:500674) reported a +1% profit before tax for the year, driven by operational efficiencies and diabetes franchise momentum.
- The company maintained leadership in the insulin segment, with Lantus holding a 31% market share in the basal segment and a volume acceleration of +6%.
- Toggio, a second-generation basal insulin, is experiencing double-digit growth, contributing to the company's strong performance in the diabetes sector.
- Sanofi India Ltd (BOM:500674) is expanding its market reach by tapping into public sector opportunities, including CGHS, ESI, railways, and defense contracts.
- The company is focusing on patient-centric, AI-enabled initiatives and innovative customer journey optimizations to enhance its market position.
- Domestic sales were flat for 2025, indicating challenges in achieving growth in the local market.
- There was a significant drop in export sales due to the divestment of the Airshawar site with Zentiva, impacting overall revenue.
- The partnership sales experienced volatility, with a notable drop in Q4 due to stock stabilization and aggressive competition in institutional business.
- Operating expenses saw a reduction, but the EBITDA margin declined to an eight-quarter low of 21.5%, raising concerns about cost management.
- The company faces challenges in stabilizing partnership sales, with fluctuations expected to continue into 2026, impacting revenue predictability.
Good evening everyone, and a very warm welcome to the investor conference call hosted by Sanofi India Limited. Joining the call, we have Mr. Deepa Karoda, Managing Director; Mr. Rashid Ayadi, whole-time director and CFO; and Mr. Hareshwala, company secretary from Sanofi India Limited.
Before we begin this investor call, there are 2 important announcements. Please note that the proceedings of this meeting are recorded.
Secondly, please note a standard disclaimer that there are certain statements in this call which may be overlooking and actual results may vary depending on various other factors which may impact the future performance.
Moving on to the agenda, we will cover the performance for the quarter and year ended December 2025 and other highlights. Thereafter we will have a Q&A session which will end exactly sharp at 5 p.m. All investors and participants are please requested to keep their questions brief and avoid repetition. (Operator Instructions)
I now hand over to the management to to take us through the presentation.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
